BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Alkem Laboratories Ltd.’s reported Q4 FY21 performance was below estimate due to lower U.S. sales, higher selling general and administrative expenses and also inventory provisioning of Rs 800 million.
Revenue growth stood at 7.0% YoY to Rs 21.9 billion (our estimate: Rs 22.4 billion) driven by strong 17.1% increase in India sales.
India business contributed ~67% to the revenues and we believe it would be the key value driver for the company.
Adjusted Ebitda margin improved 210 basis points YoY to 16.9% largely benefiting from better revenue mix.
U.S. sales were weak but we expect revenue to improve in coming quarters with new launches.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.